Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 30 of 88 · 4213 articles
The work highlights a widespread tire-derived contaminant (6PPDQ) that may worsen colitis in a mouse model by disturbing key molecular pathways; this raises questions about whether environmental pollutants could...
The study suggests a common plant compound (oxalate) may build up in the intestines of people with IBD because transporter proteins are reduced, potentially worsening inflammation. If confirmed, this could influence...
People with IBD in this study had much worse quality of life and a high burden of other medical and mental-health conditions; addressing these comorbidities could improve daily functioning and outcomes.
The study links a common dietary flavonoid, epicatechin, to restoration of a protective ILC3 subset and mucosal repair in mouse colitis via a defined molecular pathway. This could point to new therapeutic targets for...
A single agent that both highlights inflamed colon tissue on MRI and delivers anti-inflammatory therapy could improve how ulcerative colitis is monitored and treated, reducing reliance on metal contrast agents.
If you have isolated perianal fistulizing Crohn’s disease, this large multicenter cohort shows about one-third later developed luminal Crohn’s disease over long-term follow-up, but many did not — underscoring variable...
This paper links preclinical models and a short Phase 2a trial to show a candidate SIK2/SIK3 inhibitor (GLPG3970) produced anti-inflammatory and mucus-restoring signatures in IBD tissues. If findings hold in larger...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Saudi journal of gastroenterology :...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease and Research and clinical trials. The original article is from Saudi journal of...
Imaging found increased visceral fat in children with Crohn's despite normal BMI, which could reveal inflammation-related risk not apparent from weight alone. Visceral adiposity was linked to markers of inflammation and...
If validated, serum osmolality — a routine, low-cost blood measure — could become an additional marker to help identify IBD in certain hospitalized patients with anxiety. This could aid research and possibly improve...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Microbiome. The original article is from Pakistan Veterinary Journal.
This study identifies a specific gut microbe (Turicimonas muris) and an immune pathway link by which a high-fat diet reduced experimental colitis severity in mice, suggesting diet–microbiome interactions can strongly...
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from Inflammation.
Patients with ulcerative colitis may develop advanced neoplasia after seemingly complete endoscopic removal of dysplasia. Detecting genomic alterations in adjacent, histologically normal margins could identify...
Depression and GI diseases often co-occur; knowing which tends to appear first — and that this varies by subtype — can help clinicians prioritize screening and integrated care.
The study identifies specific small molecules and polysaccharide features in Atractylodes macrocephala that correlated with reduced inflammation in a mouse model of ulcerative colitis, which could guide future...
Cure8 found this source from Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, but the page could not be read reliably yet....
Genetic variation in MYO9B has been linked to Crohn’s disease, ulcerative colitis, and celiac disease. This study suggests a plausible epithelial-cell mechanism — altered microvilli and RhoA signaling — that could help...
Monogenic causes (especially IL-10RA mutations) are common in infant-onset IBD and are linked to more severe disease and higher mortality; early genetic testing and consideration of HSCT may change prognosis.
A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.
This study describes a programmable, inflammation-responsive engineered probiotic aimed at targeting IBD flares by sensing calprotectin and delivering antioxidant and epithelial-protective factors — a concept that could...
People with Crohn’s disease who develop kidney failure sometimes face limited dialysis options. This paper suggests peritoneal dialysis may work for some patients—especially those in sustained remission—but also shows...
This study suggests that cumulative infliximab exposure over time (AUC) — not just trough levels — may predict infection risk in people with IBD. That could affect how clinicians use therapeutic drug monitoring to...
A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts...
Knowing how IBD burden has changed over time and varies across states helps patients, clinicians, and health systems anticipate needs for diagnosis, specialized care, and resource planning. Rising Crohn’s burden in some...
Family history of CRC raises an individual’s absolute CRC risk whether or not they have IBD, and people with IBD who have multiple first‑degree relatives with CRC appear to have the largest increase in absolute risk....
IBD patients and clinicians may see more treatment options in the future if Lilly’s pipeline programs (notably mirikizumab and oral α4β7 inhibitors) succeed.
The 5-year PROFILE follow-up is presented as strong evidence that early, effective therapy (in this case infliximab plus an immunomodulator) can change the long-term course of Crohn’s disease by lowering surgery rates...
Cure8 found this source from magzter.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
The review directly compares randomized-trial evidence for JAK inhibitors in moderate-to-severe Crohn's disease and highlights which regimens (notably upadacitinib) showed the most consistent efficacy signals,...
People with suspected or known IBD and their clinicians want accurate, noninvasive tests to detect inflammation. This review suggests NGAL may be sensitive for identifying IBD but existing data are limited and uncertain,...
Non-invasive blood biomarkers that predict who will respond to therapy could help personalize treatment and avoid ineffective medications. This study identifies plasma miR-145 and miR-191 as potential predictors of...
The paper describes a new nanodelivery method that improves targeted delivery of 5‑ASA in preclinical models, which could eventually address limitations of oral mesalazine formulations for colonic inflammation.
If validated, a genetic marker (IL12B rs6887695) might help predict which patients are more likely to benefit from ustekinumab, potentially informing personalized treatment choices in IBD.
Children with newly diagnosed ulcerative colitis in this study commonly had reduced muscle mass (sarcopenia) at diagnosis, and the degree of muscle loss correlated with higher disease activity and inflammation....
If confirmed, starting anti‑TNF therapy (infliximab) early plus an immunomodulator may reduce surgeries, hospital admissions, and progression to complicated disease behavior over 5 years compared with a traditional...
This study suggests airborne, soil-associated microbes can change the gut microbiome and reduce colitis severity in mice — a possible explanation for lower ulcerative colitis rates in rural areas. If similar effects...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Nanomedicine.
If donor ethnicity or specific microbial/metabolite signatures influence FMT success, results could help identify optimal donors or develop targeted microbiota-based treatments for ulcerative colitis.
This trial tests a new oral drug, SAR441566, as a potential treatment for moderate-to-severe ulcerative colitis. Results could affect future treatment options if the drug is effective and safe.
This trial is testing risankizumab in children with moderate-to-severe Crohn’s disease to learn how the drug behaves in kids, whether it’s safe, and whether it reduces disease activity — information that could expand...
This trial tests a new oral drug for moderate to severe ulcerative colitis with a short (12-week) primary endpoint; people with active UC may be interested in emerging treatment options and clinical trial opportunities.
This trial tests a safe, non-drug supplement (GlcNAc) as a precision-medicine approach for Crohn's disease based on a genetic variant that affects glycosylation. If successful, it could offer a new, well-tolerated...
Ulcerative colitis changes the colonic environment in ways that can make current mesalazine formulations release unpredictably. New delivery approaches aimed at stabilising drug interfaces could lead to more consistent...
This preclinical study suggests probiotic-derived extracellular vesicles may reduce intestinal inflammation and restore barrier function via PPARγ signaling and changes to the gut microbiome—an early step toward...
Label changes affect how balsalazide is prescribed and monitored for people with ulcerative colitis. The update highlights safety risks—especially kidney, liver, and hypersensitivity concerns—and reinforces age- and...
This analysis directly addresses treatments commonly used for perianal fistulizing Crohn’s disease and compares biologic anti-TNF drugs with emerging mesenchymal stem cell therapy, information that could affect treatment...
